{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:42:56Z","timestamp":1777876976089,"version":"3.51.4"},"reference-count":85,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009010","name":"Novartis Pharmaceuticals UK Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Musculoskeletal"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:p>Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease characterized by inflammation and new bone formation in the axial skeleton. AxSpA is considered a spectrum of disease that includes two subtypes identified by the Assessment in SpondyloArthritis International Society classification criteria, namely, radiographic (r-axSpA usually referred to as ankylosing spondylitis) and non-radiographic axSpA (nr-axSpA). Although the burden of disease appears similar between the two classified subtypes, the degree of inflammation, as assessed by magnetic resonance imaging and C-reactive protein, and the degree of new bone formation are significantly higher in r-axSpA than in nr-axSpA. Nevertheless, axSpA is considered one disease with different courses. International guidelines for the management of axSpA have outlined treatment goals focused on control of signs and symptoms, inflammation, prevention of progressive structural damage, preservation of physical function, normalization of social participation and improvement of quality of life. The pathogenesis of axSpA has not been completely elucidated to date. A strong link between human leukocyte antigen B27 and axSpA, however, has been identified, and the success of anti-tumour necrosis factor and anti-interleukin (IL)-17A therapy has highlighted some of the key pro-inflammatory cytokines involved. The anti-IL-17A monoclonal antibody secukinumab is approved for the treatment of ankylosing spondylitis and nr-axSpA in the European Union and United States. In this narrative review, we discuss data for secukinumab in axSpA from randomized controlled trials, including MEASURE trials in AS and PREVENT in nr-axSpA, and real-world evidence.<\/jats:p>","DOI":"10.1177\/1759720x211041854","type":"journal-article","created":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T05:48:37Z","timestamp":1630129717000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":20,"title":["Secukinumab in axial spondyloarthritis: a narrative review of clinical evidence"],"prefix":"10.1177","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9156-5095","authenticated-orcid":false,"given":"J\u00fcrgen","family":"Braun","sequence":"first","affiliation":[{"name":"Rheumazentrum Ruhrgebiet, Landgrafenstrasse 15, D-44652 Herne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uta","family":"Kiltz","sequence":"additional","affiliation":[{"name":"Rheumazentrum Ruhrgebiet Herne, Ruhr-University, Bochum, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f6rn","family":"B\u00fchring","sequence":"additional","affiliation":[{"name":"Rheumazentrum Ruhrgebiet Herne, Ruhr-University, Bochum, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xenofon","family":"Baraliakos","sequence":"additional","affiliation":[{"name":"Rheumazentrum Ruhrgebiet Herne, Ruhr-University, Bochum, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,8,28]]},"reference":[{"key":"bibr1-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210770"},{"key":"bibr2-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.130559"},{"key":"bibr3-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa422"},{"key":"bibr4-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-020-03775-4"},{"key":"bibr5-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X20972610"},{"key":"bibr6-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208174"},{"key":"bibr7-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215707"},{"key":"bibr8-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001108"},{"key":"bibr9-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21688"},{"key":"bibr10-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212076"},{"key":"bibr11-1759720X211041854","volume":"32","author":"Kiltz U","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"bibr12-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew238"},{"key":"bibr13-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key200"},{"key":"bibr14-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211734"},{"key":"bibr15-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1002\/art.41042"},{"key":"bibr16-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key217"},{"key":"bibr17-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X09359728"},{"key":"bibr18-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2018.12.002"},{"key":"bibr19-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1885-z"},{"key":"bibr20-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215356"},{"key":"bibr21-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3794"},{"key":"bibr22-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01682"},{"key":"bibr23-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505066"},{"key":"bibr24-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X20986734"},{"key":"bibr25-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219406"},{"key":"bibr26-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-216980"},{"key":"bibr27-1759720X211041854","unstructured":"European Medicines Agency (EMA). COSENTYX\u00ae (secukinumab). Summary of product characteristics, http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003729\/WC500183129.pdf (2021, accessed 9 July 2021)."},{"key":"bibr28-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2016.1167183"},{"key":"bibr29-1759720X211041854","unstructured":"US Food & Drug Administration (FDA). COSENTYX\u00ae (secukinumab). Highlights of prescribing information, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125504s035lbl.pdf (2021, accessed 9 July 2021)."},{"key":"bibr30-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1490-y"},{"key":"bibr31-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-018-0123-5"},{"key":"bibr32-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000001099"},{"key":"bibr33-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1002\/art.41477"},{"key":"bibr34-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108217"},{"key":"bibr35-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-015-0522-3"},{"key":"bibr36-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30066-7"},{"key":"bibr37-1759720X211041854","first-page":"260","volume":"37","author":"Deodhar A","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"bibr38-1759720X211041854","doi-asserted-by":"crossref","unstructured":"Marzo-Ortega H, Miceli-Richard C, Gill S, et al. Subcutaneous secukinumab 150 mg provides sustained relief in total and nocturnal back pain, morning stiffness, fatigue, and low disease activity in patients with active ankylosing spondylitis: end-of-study (5-year) data from the MEASURE 2 trial (Abstract 0364). Arthritis Rheumatol 2020; 72, https:\/\/acrabstracts.org\/abstract\/subcutaneous-secukinumab-150-mg-provides-sustained-relief-in-total-and-nocturnal-back-pain-morning-stiffness-fatigue-and-low-disease-activity-in-patients-with-active-ankylosing-spondylitis-end-of\/","DOI":"10.1093\/rheumatology\/keaa111.241"},{"key":"bibr39-1759720X211041854","doi-asserted-by":"crossref","unstructured":"Marzo-Ortega H, Miceli-Richard C, Gill S, et al. Subcutaneous secukinumab 150 mg provides rapid and sustained relief in total and nocturnal back pains, morning stiffness, and fatigue in patients with active ankylosing spondylitis over 4 years (Abstract 1504). Arthritis Rheumatol 2019; 71, https:\/\/acrabstracts.org\/abstract\/subcutaneous-secukinumab-150-mg-provides-rapid-and-sustained-relief-in-total-and-nocturnal-back-pains-morning-stiffness-and-fatigue-in-patients-with-active-ankylosing-spondylitis-over-4-years\/","DOI":"10.1093\/rheumatology\/keaa111.241"},{"key":"bibr40-1759720X211041854","unstructured":"Marzo-Ortega H, Deodhar A, Blanco R, et al. Secukinumab improves pain, morning stiffness, fatigue and physical function in tumor necrosis factor inhibitor-na\u00efve patients with non-radiographic axial spondyloarthritis: results from a randomized controlled phase III study (Abstract 1340). Arthritis Rheumatol 2020; 72(Suppl. 10), https:\/\/acrabstracts.org\/abstract\/secukinumab-improves-pain-morning-stiffness-fatigue-and-physical-function-in-tumor-necrosis-factor-inhibitor-naive-patients-with-non-radiographic-axial-spondyloarthritis-results-from-a-randomized-c\/"},{"key":"bibr41-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.299"},{"key":"bibr42-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24517."},{"key":"bibr43-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-02262-4"},{"key":"bibr44-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-019-0819-8"},{"key":"bibr45-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-019-00176-5"},{"key":"bibr46-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20575"},{"key":"bibr47-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-020-00269-6"},{"key":"bibr48-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11102"},{"key":"bibr49-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1002\/art.38921"},{"key":"bibr50-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-eular.3031"},{"key":"bibr51-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.1.20"},{"key":"bibr52-1759720X211041854","doi-asserted-by":"crossref","first-page":"i35","DOI":"10.1093\/rheumatology\/kew056","volume":"55","author":"Emery P","year":"2016","journal-title":"Rheumatology"},{"key":"bibr53-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-216988"},{"key":"bibr54-1759720X211041854","volume":"76","author":"Deodhar A","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"bibr55-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S149494"},{"key":"bibr56-1759720X211041854","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1136\/annrheumdis-2017-212820","volume":"78","author":"Poddubnyy D.","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"bibr57-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2018.1477591"},{"key":"bibr58-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key375"},{"key":"bibr59-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209730"},{"key":"bibr60-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1911-1"},{"key":"bibr61-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-020-00886-7"},{"key":"bibr62-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex081"},{"key":"bibr63-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-eular.3008"},{"key":"bibr64-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000755"},{"key":"bibr65-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.561748"},{"key":"bibr66-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2018.1538004"},{"key":"bibr67-1759720X211041854","first-page":"897","volume":"78","author":"van der Horst-Bruinsma I","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"bibr68-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210023"},{"key":"bibr69-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.1448"},{"key":"bibr70-1759720X211041854","unstructured":"Deodhar A, Mease P, Machado P, et al. Impact of age and disease duration on the response to IL-17A inhibitor (secukinumab) treatment in ankylosing spondylitis: pooled results from the phase 3 MEASURE studies. Arthritis Rheumatol 2019; 71, https:\/\/acrabstracts.org\/abstract\/impact-of-age-and-disease-duration-on-the-response-to-il-17a-inhibitor-secukinumab-treatment-in-ankylosing-spondylitis-pooled-results-from-the-phase-3-measure-studies\/"},{"key":"bibr71-1759720X211041854","unstructured":"Braun J. Secukinumab improved signs and symptoms in patients with non-radiographic axial spondyloarthritis: results from a randomized controlled phase III study stratified by baseline objective signs of inflammation (Abstract 1366). Arthritis Rheumatol 2020; 72, https:\/\/acrabstracts.org\/abstract\/secukinumab-improved-signs-and-symptoms-in-patients-with-non-radiographic-axial-spondyloarthritis-results-from-a-randomized-controlled-phase-iii-study-stratified-by-baseline-objective-signs-of-inflam\/"},{"key":"bibr72-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.5118"},{"key":"bibr73-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214273"},{"key":"bibr74-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.3257"},{"key":"bibr75-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0805-y"},{"key":"bibr76-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05423-7"},{"key":"bibr77-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01352-8"},{"key":"bibr78-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001280"},{"key":"bibr79-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23534"},{"key":"bibr80-1759720X211041854","doi-asserted-by":"crossref","unstructured":"Kiltz U, Brandt-J\u00fcrgens J, K\u00e4stner P, et al. How do TNF-alpha-inhibitors in medical history affect patient reported outcomes and retention in ankylosing spondylitis patients treated with secukinumab in real world? \u2013 German observational study (Abstract 0354). Arthritis Rheumatol 2020; 72, https:\/\/acrabstracts.org\/abstract\/how-do-tnf-alpha-inhibitors-in-medical-history-affect-patient-reported-outcomes-and-retention-in-ankylosing-spondylitis-patients-treated-with-secukinumab-in-real-world-german-observational\/","DOI":"10.1136\/annrheumdis-2020-eular.220"},{"key":"bibr81-1759720X211041854","first-page":"888","volume":"78","author":"Michelson B","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"bibr82-1759720X211041854","first-page":"484","volume":"78","author":"Ogdie A","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"bibr83-1759720X211041854","first-page":"1814","volume":"78","author":"Kiltz U","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"bibr84-1759720X211041854","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1136\/annrheumdis-2018-214529","volume":"78","author":"Kiltz U","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"bibr85-1759720X211041854","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.2263"}],"container-title":["Therapeutic Advances in Musculoskeletal Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1759720X211041854","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1759720X211041854","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1759720X211041854","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:37:49Z","timestamp":1777588669000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1759720X211041854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":85,"alternative-id":["10.1177\/1759720X211041854"],"URL":"https:\/\/doi.org\/10.1177\/1759720x211041854","relation":{},"ISSN":["1759-720X","1759-7218"],"issn-type":[{"value":"1759-720X","type":"print"},{"value":"1759-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]},"article-number":"1759720X211041854"}}